Earnings call · Apr–Jun 2026
Gufic BioSciences Ltd.
Apr–Jun 2026 revenue grew to ₹261 crore from ₹227 crore from a year earlier; EBITDA margin expanded to 18.09% from 14.6%. Management expects 15-20% growth from a year earlier & is scaling Indore capacity to 40-45% by year-end while expanding international operations via own field teams in emerging markets.
The full notes: the guidance, numbers & KPIs, strategy, outlook, risks, what analysts asked.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
From the company
- Ami ShahCOMPANY SECRETARY
- Avik DasInvestor Relations
- Pranav ChoksiCEO & Whole-Time Director
- Devkinandan RoonghtaChief Financial Officer
Questions came from
- BhavyaSamaasa Capital
- Aarav
- Agam Shah
- Nitya ShahKamayaKya Wealth Management
- Arvind AroraA Square Capital
- AmeyaValue Equity
Topics in this call
Opening remarks
Ami ShahCOMPANY SECRETARY
Gufic Biosciences LimitedAugust 17, 2026Page 2 of 12Moderator: Ladies and gentlemen, Good day, and welcome to Gufic Biosciences Limited Q1 FY27 Earnings Conference Call. As a reminder, all participants' lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand over the conference to Ms. Ami Shah from Gufic Biosciences Limited. Thank you, and over to you, ma'am.
Read the whole call: 90 paragraphs, 6 analysts' questions with every answer, 8 marked passages.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript as the company filed it on BSE. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.